Cue Biopharma Inc (1UC.SG)
- Simply Wall St.
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Cue Biopharma ( NASDAQ:CUE ) First Quarter 2024 Results Key Financial Results Revenue: US$1.72m (up by US$1.53m from 1Q...
- GlobeNewswire
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells, today provided a business and financial update for the first quarter 2024. Recent Business Highlights CUE-101 abstract accepted for an oral presentation and poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for
- GlobeNewswire
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually. Presentation Details Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m
